tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Mirxes Partners with PT Diastika Biotekindo for Cancer Diagnostics in Indonesia

Story Highlights
  • Mirxes collaborates with PT Diastika Biotekindo for cancer diagnostics in Indonesia.
  • The partnership aims to improve early cancer detection in Indonesia’s healthcare market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Mirxes Partners with PT Diastika Biotekindo for Cancer Diagnostics in Indonesia

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Mirxes Holding Company Limited ( (HK:2629) ) has issued an update.

Mirxes Holding Company Limited has entered into a memorandum of understanding with PT Diastika Biotekindo to collaborate on the registration and commercialization of molecular diagnostic tests for cancer detection in Indonesia. This collaboration aims to address Indonesia’s significant cancer burden by improving early detection rates, leveraging PT Diastika Biotekindo’s extensive hospital network and Mirxes’ innovative diagnostic technologies.

More about Mirxes Holding Company Limited

Mirxes Holding Company Limited, incorporated in the Cayman Islands, is involved in the development and commercialization of molecular diagnostic tests, focusing on early detection and diagnosis of high incidence and high mortality cancers.

Average Trading Volume: 1,131,713

Current Market Cap: HK$9.81B

For detailed information about 2629 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1